Skip to main content

Latest SEC Filings — Page 152

Most recent SEC EDGAR filings across all covered tickers, sorted chronologically. Wiseek AI reads each filing and scores it 1–10 for market-moving potential; click through for full analysis.

How Wiseek curates this list

Every filing on this page is sourced directly from SEC EDGAR, the U.S. Securities and Exchange Commission's public filings system. Wiseek processes 8-K, 10-K, 10-Q, Form 4, Form 144, DEF 14A, Schedule 13D/A and related disclosures filed by U.S.-listed companies. The original filing is always linked from each article so readers can verify the source document directly.

How filings get scored

Each filing runs through Wiseek's importance scorer, which weights filing type, deal magnitude, insider participation, material-event flags (going-concern, restatements, executive transitions, M&A) and historical market-reaction patterns. Filings scoring below 7 on the 1–10 scale are filtered out at the database query so this list stays focused on market-moving disclosures. See our methodology for the full rubric.

Editorial standards

Wiseek does not edit the underlying SEC filing. Plain-English summaries and key-event extractions are generated from the verified source text and clearly attributed as AI-generated. Wiseek does not provide investment advice — see our editorial policy for full standards on accuracy, source disclosure, and corrections.

Track by company

Follow all SEC filings for a specific company by visiting its ticker page: AAPL, MSFT, NVDA, TSLA, AMZN, GOOGL, META, JPM, V, UNH, XOM, AVGO, LLY, MA, COST, JNJ, PG, HD, ABBV, MRK, KO, NFLX, AMD, WMT, CVX, BAC — or browse all covered tickers.

Stockholders Approve Royal Cup Merger, Finalizing Acquisition Path
ProForm 8-KFARM · Form 8-K · 8d ago
DAAQ Files S-4 for Old Glory Merger: Significant Dilution & Going Concern Risks Highlighted
ProForm S-4/ADAAQ · Form S-4/A · 8d ago
Medicus Pharma Finalizes Proxy for Aggressive 1-for-50 Reverse Split to Avoid Nasdaq Delisting
ProForm DEF 14AMDCX · Form DEF 14A · 8d ago
GRUPO TMM Reports Steep Decline in Q1 2026 Revenue and Net Income Amidst Contract Expirations
ProForm 6-KGTMAY · Form 6-K · 8d ago
AI Financial Corp Rebrands, Changes Ticker to AIFC for AI-Driven Strategic Shift
Form 8-KALTS · Form 8-K · 8d ago
Director Acquires $5 Million in Common Stock at IPO Price Following Company's Public Offering
Form 4AVLN · Form 4 · 8d ago
Senstar Reports Improved Net Income & Strategic LiDAR Acquisition Amidst Operating Cash Flow Decline
ProForm 20-FSNT · Form 20-F · 8d ago
Major Shareholder Ernest Garcia II Details Sale of Covered Call Options on 4 Million Shares
ProForm SCHEDULE 13D/ACVNA · Form SCHEDULE 13D/A · 8d ago
Shareholders to Vote on Dual-Class Structure, Control Shift, Massive Share Increase, and Reverse Stock Split Authorization
ProForm 6-KFOFO · Form 6-K · 8d ago
10% Owner Ernest C. Garcia II Sells $272M in Carvana Covered Call Options
Form 4CVNA · Form 4 · 8d ago
Final Prospectus Filed for Resale of 293.8M Shares, Creating Significant Market Overhang
Form 424B3XNDU · Form 424B3 · 8d ago
10% Owner Files Intent to Sell $1.58 Billion in Carvana Stock
Form 144CVNA · Form 144 · 8d ago
Thomson Reuters Finalizes $605M Cash Distribution & Share Consolidation Terms
ProForm 6-KTRI · Form 6-K · 8d ago
Illumina Authorizes New $1.5 Billion Share Repurchase Program Amidst Solid Q1 Results and SomaLogic Acquisition Details
ProForm 10-QILMN · Form 10-Q · 8d ago
Cambium Networks Faces Substantial Doubt as Going Concern, Defaults on Debt, and Delists from Nasdaq
ProForm 10-KCMBM · Form 10-K · 8d ago
Seaport Therapeutics Prices Initial Public Offering at $18.00 Per Share, Raising $254.88 Million for Clinical Development
ProForm 424B4SPTX · Form 424B4 · 9d ago
Major Shareholder White Mountains Reduces Board Representation
Form SCHEDULE 13D/AMAX · Form SCHEDULE 13D/A · 9d ago
authID Secures $3.77M in Senior Secured Debentures and Warrants to Address Going Concern
ProForm 8-KAUID · Form 8-K · 9d ago
Proxy Details Reveal $1.23M Executive Severance Amidst Going Concern Risks
Form 8-KNEXM · Form 8-K · 9d ago
Biotricity Restructures Capital, Creating Highly Dilutive Series C Preferred Stock with 59.6% Conversion Trigger
ProForm 8-KBTCY · Form 8-K · 9d ago
SPAC Seeks Shareholder Approval to Extend Business Combination Deadline to June 2027 Amidst Going Concern Warning
ProForm PRE 14ATDAC · Form PRE 14A · 9d ago
Executive Chairman Vincent LoPriore and Affiliates Disclose 21.46% Stake in Hepion Pharmaceuticals
ProForm SCHEDULE 13DCTRVP · Form SCHEDULE 13D · 9d ago
Nixxy Registers Over 1.69M Shares for Resale by Selling Stockholders, Adding to Market Overhang
Form S-3NIXX · Form S-3 · 9d ago
HNO International Secures Highly Dilutive $30M Equity Line to Address Going Concern
ProForm 8-KHNOI · Form 8-K · 9d ago
Secures $11M in Highly Restrictive Debt Financing with Extensive Collateral and Punitive Default Terms
ProForm 8-KSCNX · Form 8-K · 9d ago
Eightco Holdings Expands Strategic Asset Strategy with Worldcoin Tower, Committing to Long-Term, High-Fee Agreement
ProForm 8-KORBS · Form 8-K · 9d ago
Director Resigns as Major Shareholder GBL Reduces Stake Below Board Nomination Threshold
ProForm 8-KCNXC · Form 8-K · 9d ago
Helio Corp Settles $879K Debt with Creditor via Equity Sales, Introducing Significant Share Overhang
ProForm 8-KHLEO · Form 8-K · 9d ago
Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer
Form 6-KEPRX · Form 6-K · 9d ago
DevvStream Secures $250K in Private Placement of Pre-Funded Warrants at Premium to Market Price
ProForm 8-KDEVS · Form 8-K · 9d ago